Immunoblot analyses of chimpanzee sera after infection and after immunization and challenge with Mycoplasma pneumoniae
- PMID: 8112834
- PMCID: PMC186217
- DOI: 10.1128/iai.62.3.1008-1014.1994
Immunoblot analyses of chimpanzee sera after infection and after immunization and challenge with Mycoplasma pneumoniae
Abstract
Consecutive weekly or biweekly serum specimens obtained during a 3- or 4-month study from 16 chimpanzees were examined by immunoblot analyses to identify the immunogenic components of Mycoplasma pneumoniae. Six experimentally infected chimpanzees showed significant signs of overt disease, including cough, pharyngitis, rhinitis, fever, and loss of appetite. The sera of these infected chimpanzees recognized from 17 to 20 protein bands. Two control chimpanzees that were not inoculated were included in the study. Three chimpanzees immunized with a formalin-inactivated OSU-1A vaccine and three chimpanzees immunized with an experimental acellular vaccine showed minimal signs of disease on challenge. After challenge, the serum immunoblot responses of the immunized chimpanzees were similar to those of the infected chimpanzees. Before challenge, the sera of two previously infected chimpanzees recognized protein bands of 169 (which comigrated with the P1 adhesin), 148, 130, 117, 86, 61, 44, 35, 30, and 29 kDa. After challenge, the previously infected chimpanzees showed the most intense serum immunoblot responses and were most protected against colonization and disease. The sera from each of the 16 chimpanzees examined recognized a large number of immunogenic components, and the serum immunoblot responses were virtually identical to those of patients. Sera from each chimpanzee and patient recognized 169-, 148-, 130-, 117-, 86-, 44-, and 35-kDa bands and many of them recognized 67-, 63-, 61-, 56-, 32-, 30-, and 29-kDa protein bands.
Similar articles
-
Protection of immunized and previously infected chimpanzees challenged with Mycoplasma pneumoniae.Vaccine. 1994 Jun;12(8):707-14. doi: 10.1016/0264-410x(94)90220-8. Vaccine. 1994. PMID: 8091848
-
Relationship between an 85 kDa protein and the protective effects of Mycoplasma pneumoniae.Microbiol Immunol. 1992;36(5):455-64. doi: 10.1111/j.1348-0421.1992.tb02044.x. Microbiol Immunol. 1992. PMID: 1513262
-
Detection of antibodies to Mycoplasma pneumoniae adhesion P1 in serum specimens from infected and non-infected subjects by immunoblotting.Diagn Microbiol Infect Dis. 1996 Nov-Dec;26(3-4):141-3. doi: 10.1016/s0732-8893(96)00216-7. Diagn Microbiol Infect Dis. 1996. PMID: 9078450
-
Immunization against Mycoplasma pneumoniae disease: a review.Isr J Med Sci. 1984 Oct;20(10):912-5. Isr J Med Sci. 1984. PMID: 6439678 Review.
-
[Immunoprophylaxis of mycoplasmosis (a review of the literature)].Voen Med Zh. 1981 Jan;(1):40-4. Voen Med Zh. 1981. PMID: 6782753 Review. Russian. No abstract available.
Cited by
-
Mycoplasma pneumoniae and its role as a human pathogen.Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004. Clin Microbiol Rev. 2004. PMID: 15489344 Free PMC article. Review.
-
Molecular biology and pathogenicity of mycoplasmas.Microbiol Mol Biol Rev. 1998 Dec;62(4):1094-156. doi: 10.1128/MMBR.62.4.1094-1156.1998. Microbiol Mol Biol Rev. 1998. PMID: 9841667 Free PMC article. Review.
-
The proline-rich P65 protein of Mycoplasma pneumoniae is a component of the Triton X-100-insoluble fraction and exhibits size polymorphism in the strains M129 and FH.J Bacteriol. 1995 Jun;177(12):3370-8. doi: 10.1128/jb.177.12.3370-3378.1995. J Bacteriol. 1995. PMID: 7768845 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources